VYNE Therapeutics Inc. (VYNE)
2.62
0.10 (3.97%)
At close: Feb 20, 2025, 3:59 PM
2.55
-2.67%
After-hours: Feb 20, 2025, 04:29 PM EST
undefined% (undefined)
| Bid | 2.33 |
| Market Cap | 38.65M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 3.29 |
| PE Ratio (ttm) | 0.8 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.77 |
| Volume | 145,009 |
| Avg. Volume (20D) | 105,613 |
| Open | 2.57 |
| Previous Close | 2.52 |
| Day's Range | 2.57 - 2.71 |
| 52-Week Range | 1.57 - 4.30 |
| Beta | undefined |
About VYNE
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is als...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 25, 2018
Employees 10
Stock Exchange NASDAQ
Ticker Symbol VYNE
Website https://www.vynetherapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VYNE stock is "Buy." The 12-month stock price forecast is $6.88, which is an increase of 162.60% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
VYNE Therapeutics Inc. is scheduled to release its earnings on Mar 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
